Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 7/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | HTR1D | P28221 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28386012 | 0.84 | HTR1B (0.48) | HTR1BSLC6A4SLC6A2HTR1D | |
| SCHEMBL6447973 | 0.81 | HTR1B (0.57) | HTR1BSLC6A4SLC6A2HTR1DHTR2A | |
| SCHEMBL8536438 | 0.80 | SLC6A4 (0.48) | HTR1BSLC6A4SLC6A2HTR1DKDM4E | |
| SCHEMBL6447975 | 0.80 | HTR1B (0.56) | HTR1BSLC6A4SLC6A2HTR1DHTR2A | |
| SCHEMBL8540012 | 0.77 | SLC6A4 (0.47) | HTR1BSLC6A4SLC6A2HTR1DKDM4E | |
| SCHEMBL15501176 | 0.75 | HTR1B (1.00) | HTR1BSLC6A4HTR1DHRH1KDM4E | |
| SCHEMBL9995405 | 0.74 | SLC6A4 (0.67) | HTR1BSLC6A4SLC6A2CACNA2D1 | |
| SCHEMBL7275543 | 0.74 | HTR1B (1.00) | HTR1BSLC6A4HTR1DHRH1KDM4E | |
| SCHEMBL2599841 | 0.74 | HTR1B (0.52) | HTR1BSLC6A4SLC6A2HTR1DKDM4E | |
| SCHEMBL27808855 | 0.74 | HTR1B (0.50) | HTR1BSLC6A4SLC6A2HTR1DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | HTR1B 760/4885SLC6A4 2808/4885SLC6A2 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.